Amaç: Behçet hastalığı (BH)'nda vasküler tutulum genellikle derin ven trombozu (DVT) şeklinde olmaktadır. Bu çalışmada, DVT gelişen Behçet hastalarında immünsupresif tedaviyle kom- bine edilen farmakomekanik trombektomi (FMT) yönteminin uygulanabilirliğini ve bu yöntemin klinik iyileşme üzerine olan etkilerinin bir yıllık sonuçlarının sunulması amaçlanmıştır. Gereç ve Yöntemler: Alt ekstremite akut veya subakut, ilk atak DVT tanısıyla kliniğimize yönlendirilen ve FMT uygulanan 27 Behçet hastası çalışmaya alındı. Hastalara, işlemden önce geçici vena kava in- ferior filtresi yerleştirildi ve işlemden sonra kateter yardımıyla 24 saat boyunca 1 mg/saat doku plazminojen aktivatörü (tPA) infüzyonu uygulandı. Takipte, hastaların fizik muayeneleri ve Villalta skorlaması yapıldı. Derin venöz sistem reflü süreleri 3. 6. ve 12. aylarda Doppler ultrasonografi (USG) ile değerlendirildi. Bulgular: Yirmi yedi (22 erkek ve 5 kadın) hastanın yaş ortalaması 28,8±5,8 yıl idi. BH'nın ortalama süresi 19,5±13,5 ay ve semptomların başlama süresi ortalama 6,4±4,0 gün bulundu. On yedi hastada femoropopliteal DVT ve 10 hastada iliofemoral DVT saptandı. Altı hastada bilateral femoropopliteal segment trombozu mevcuttu. FMT yöntemi, 33 alt ekstremiteye uy- gulandı ve işlemin ortalama süresi 104±23 dk idi. Yirmi (%74) hastada trombüsün tamamen uzaklaştırıldığı Grade III akım, 3 (%11)'ünde Grade II (%50-99) akım elde edildi. Altıncı ay takibinde iki hastada tekrarlayan DVT atağı gelişti. Villalta skoruna göre, on ikinci ay takibinde, altı hastada hafif posttrombotik sendrom (PTS) ve dört hastada ılımlı PTS kliniği saptandı. Sonuç: İlk atak akut veya subakut DVT ile başvuran seçilmiş Behçet hastalarında, immünsupresif ve antikoagülan tedaviye ek olarak, FMT yöntemi ile trombüs yükünün azaltılmasının faydalı olabileceği düşünülmektedir. Ülkemizde BH'nın yaygın olması nedeni ile, bu hastalarda gelişen venöz tutulum tedavisini optimal düzeyde sağlayabilmek için daha kapsamlı ve karşılaştırmalı çalışmalara ihtiyaç vardır.
Anahtar Kelimeler: Behçet hastalığı; derin ven trombozu; posttrombotik sendrom
Objective:Vascular involvement in Behçet's disease (BD) is usually seen as deep vein thrombosis (DVT). We aimed to investigate the feasibility of pharmacomechanical thrombolytic (PMT) method for treatment of venous involvement in Behçet's patients and its one year results on clinical improvement. Material and Methods: Twenty-seven BD patients who referred to our clinic with the lower extremity acute DVT and underwent PMT were included in the study. Temporary vena cava inferior filter was placed before the procedure and 1 mg/h of tissue plasminogen activator (tPA) infusion was applied to patients for 24 hours via catheter. Follow-up examinations included physical examinations and Villalta scoring. Venous reflux was evaluated by Doppler ultrasonography (USG) follow-up at months 3, 6 and 12. Results: The mean age of 27 (22 males and 5 females) patients was 28.8±5.8 years. The duration of BD was 19.5±13.5 months and duration of onset of symptoms was 6.4 ± 4.0 days. 17 patients had femoropopliteal DVT and 10 patients had iliofemoral DVT. Six patients had bilateral femoropopliteal thrombosis. PMT was performed in 33 lower extremities and the mean duration of the procedure was 104±23 min. 20 (74%) patients had Grade III (complete lysis) flow and 3 (11%) patients had Grade II (50-99%) flow. Recurrent DVT was detected in 2 patients follow-up at 6 month. According to Villalta score, six patients had mild post-thrombotic syndrome (PTS) and four patients had moderate PTS. Conclusion: In addition to immunosuppressive and anticoagulant therapy, it may be beneficial to reduce thrombus burden by FMT method in selected patients with Behcet's disease who presented with acute or subacute DVT. Because of the high prevalence of BD in our country, comparative and more comprehensive studies are needed to provide optimal treatment of venous involvement in these patients.
Keywords: Behcet's disease; deep venous thrombosis; post-thrombotic syndrom
- Seyahi E, Yurdakul S. Behçet?s syndrome and thrombosis. Mediterr J Hematol Infect Dis. 2011;3(1):e2011026. [Crossref] [PubMed] [PMC]
- Alibaz-Oner F, Karadeniz A, Yılmaz S, Balkarlı A, Kimyon G, Yazıcı A, et al. Behçet disease with vascular involvement: effects of different therapeutic regimens on the ıncidence of new relapses. Medicine (Baltimore). 2015;94(6):e494. [Crossref] [PubMed] [ PMC]
- Genadiev GG, Mortola L, Arzedi R, Deiana G, Spanu F, Camparini S. Surgical treatment of angio-Behçet. Behcet?s disease. InTech. 2017. Doi: 10.5772/intechopen.68664. [Cross ref]
- Sarica-Kucukoglu R, Akdag-Kose A, Kayaball M, Yazganoglu KD, Disci R, Erzengin D, et al. Vascular involvement in Behcet?s disease: a retrospective analysis of 2319 cases. Int J Dermatol. 2006;45(8):919-21. [Crossref] [PubMed]
- Güngen AC, Çoban H, Aydemir Y, Düzenli H. Consider Behcet?s disease in young patients with deep vein thrombosis. Respir Med Case Rep. 2016;18:41-4. [Crossref ]
- Cakmak OS, Seyahi E, Kantarci F, Yesilova A, Ergin AS, Dikici AS, et al. Venous severity assessment in Behçet?s syndrome. Clin Exp Rheumatol. 2010;28(4):S139.
- Demirtü rk OS, ̈Tunel HA, Alemdaroğlu U. V-a cular manifestations of Behçet?s disease. Behcet?s disease: InTech. 2017. Doi: 10.5772/ intechopen.68765.
- Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain A, Gul A, et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis. 2009;68(10):1528-34. [Crossref] [PubMed]
- Vedantham S, Sista AK, Klein SJ, Nayak L, Razavi MK, Kalva SP, et al. Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal. J Vasc Interv Radiol. 2014;25(9):1317-25. [Crossref] [PubMed]
- Köksoy C, Yilmaz MF, Başbuğ HS, Calik ES, Erkut B, Kaygın MA, et al. Pharmacomechanical thrombolysis of symptomatic acute and subacute deep vein thrombosis with a rotational thrombectomy device. J Vasc Interv Radiol. 2014;25(12):1895-900. [Crossref] [PubMed]
- Soosainathan A, Moore HM, Gohel MS, Davies AH. Scoring systems for the postthrombotic syndrome. J Vasc Surg. 2013; 57(1):254-61. [Crossref ] [PubMed]
- Bush RL, Lin PH, Bates JT, Mureebe L, Zhou W, Lumsden AB. Pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis: safety and feasibility study. J Vasc Surg. 2004;40(5):965-70. [Crossref ] [PubMed]
- Lin PH, Zhou W, Dardik A, Mussa F, Kougias P, Hedayati N, et al. Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis. Am J Surg. 2006;192(6):782-8. [Crossref] [PubMed]
- Rao AS, Konig G, Leers SA, Cho J, Rhee RY, Makaroun MS, et al. Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis: an alternative in patients with contraindications to thrombolysis. J Vasc Surg. 2009;50(5):1092-8. [Crossref ] [PubMed]
- Chaudhry MA, Pappy R, Hennebry TA. Use of the trellis device in the management of deep vein thrombosis: a retrospective single-center experience. J Invasive Cardiol. 2013;25(6): 296-9. [PubMed ]
- Galanaud JP, Kahn SR. The post-thrombotic syndrome: a 2012 therapeutic update. Curr Treat Options Cardiovasc Med. 2013;15(2): 153-63. [Crossref ] [PubMed]
- Kahn SR. How I treat postthrombotic syndrome. Blood. 2009;114(21):4624-31. [Cross ref] [PubMed]
- Alibaz-Oner F, Aldag B, Aldag M, Unal AU, Mutiş A¸ Toptas T, et al. Post-thrombotic syndrome and venous disease-specific quality of life in patients with vascular Behçet?s disease. J Vasc Surg Venous Lymphat Disord. 2016;4(3):301-6. [Crossref ] [PubMed]
- Grewal NK, Martinez JT, Andrews L, Comerota AJ. Quantity of clot lysed after catheterdirected thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity. J Vasc Surg. 2010;51(5):1209-14. [Crossref ] [PubMed]
.: Process List